• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 8:52:52 AM ET
    $NEOS
    Major Pharmaceuticals
    Health Care
    Get the next $NEOS alert in real time by email
    SC 13G/A 1 zk2125589.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

    SCHEDULE 13G

     (Amendment No. 2)*

    Neos Therapeutics, Inc.
    (Name of Issuer)

    Common Stock, $0.001 par value
     (Title of Class of Securities)

    64052L106
     (CUSIP Number)

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     ☐ Rule 13d-1(b)

    ⌧ Rule 13d-1(c)

     ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 64052L106
    13G
     Page 2 of 10 Pages

    1
    NAME OF REPORTING PERSONS
     
    Moshe Arkin
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)
    (a)  ☐
    (b)  ⌧
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    ---
    6
    SHARED VOTING POWER

    ---
    7
    SOLE DISPOSITIVE POWER
     
    ---
    8
    SHARED DISPOSITIVE POWER
     
    ---
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    ---
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    0.00%
    12
    TYPE OF REPORTING PERSON (See instructions)
     
    IN

    2



    CUSIP No. 64052L106
    13G
     Page 3 of 10 Pages

    1
    NAME OF REPORTING PERSONS
     
    Sphera Funds Management Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)
    (a)  ☐
    (b)  ⌧
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    ---
    6
    SHARED VOTING POWER

    ---
    7
    SOLE DISPOSITIVE POWER
     
    ---
    8
    SHARED DISPOSITIVE POWER
     
    ---
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    ---
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    0.00%
    12
    TYPE OF REPORTING PERSON (See instructions)
     
    CO

    3


    CUSIP No. 64052L106
    13G
     Page 4 of 10 Pages

    1
    NAME OF REPORTING PERSONS
     
    Sphera Global Healthcare GP Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)
    (a)  ☐
    (b)  ⌧
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    ---
    6
    SHARED VOTING POWER

    ---
    7
    SOLE DISPOSITIVE POWER
     
    ---
    8
    SHARED DISPOSITIVE POWER
     
    ---
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    ---
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    0.00%
    12
    TYPE OF REPORTING PERSON (See instructions)
     
    CO


    4


    CUSIP No. 64052L106
    13G
     Page 5 of 10 Pages

    1
    NAME OF REPORTING PERSONS
     
    Sphera Global Healthcare Management LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)
    (a)  ☐
    (b)  ⌧
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Israel
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
    ---
    6
    SHARED VOTING POWER

    ---
    7
    SOLE DISPOSITIVE POWER
     
    ---
    8
    SHARED DISPOSITIVE POWER
     
    ---
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    ---
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    0.00%
    12
    TYPE OF REPORTING PERSON (See instructions)
     
    CO

    5


    Item 1. (a)
    Name of Issuer:

    Neos Therapeutics, Inc.

                 (b)
    Address of Issuer's Principal Executive Offices:

    2940 N. Hwy 360, Grand Prairie, TX 75050

    Item 2. (a)
    Name of Person Filing:

    Moshe Arkin

    Sphera Funds Management Ltd.

    Sphera Global Healthcare GP Ltd.

    Sphera Global Healthcare Management LP


    (b)
    Address of Principal Business Office:

    Moshe Arkin – 6 Hachoshlim St., Herzelia, Israel

    Sphera Funds Management Ltd. – 21 Ha'arba'ah Street, Tel Aviv 64739, Israel

    Sphera Global Healthcare GP Ltd. – 21 Ha'arba'ah Street, Tel Aviv 64739, Israel

    Sphera Global Healthcare Management LP – 21 Ha'arba'ah Street, Tel Aviv 64739, Israel


    (c)
    Citizenship:

    Moshe Arkin – Israel

    Sphera Funds Management Ltd. – Israel

    Sphera Global Healthcare GP Ltd. – Israel

    Sphera Global Healthcare Management LP – Israel


    (d)
    Title of Class of Securities:

    Common Stock, $0.001 par value


    (e)
    CUSIP Number:

    64052L106

    6

    Item 3.
    Not applicable.

    Item 4.
    Ownership:


    (a)
    Amount beneficially owned:

    See row 9 of cover page of each reporting person.


    (b)
    Percent of class:

    See row 11 of cover page of each reporting person


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote:

    See row 5 of cover page of each reporting person


    (ii)
    Shared power to vote or to direct the vote:

    See row 6 of cover page of each reporting person and note in Item 4(a) above


    (iii)
    Sole power to dispose or to direct the disposition of:

    See row 7 of cover page of each reporting person


    (iv)
    Shared power to dispose or to direct the disposition of:

    See row 8 of cover page of each reporting person and note in Item 4(a) above

    Item 5.
    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another:

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group:

    Not applicable.

    7


    Item 9.
    Notice of Dissolution of Group:

    Not applicable.

    Item 10.
    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    8

     SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    February 10, 2021
     
       
    Moshe Arkin
     
    /s/ Moshe Arkin
    By: Moshe Arkin
     
    Sphera Funds Management Ltd.

    /s/ Ori Goldfarb
    By: Ori Goldfarb
    Title: Chief Executive Officer

    Sphera Global Healthcare GP Ltd.

    /s/ Ori Goldfarb
    By: Ori Goldfarb
    Title: Chief Executive Officer

    Sphera Global Healthcare Management LP

    /s/ Doron Breen
    By: Doron Breen
    Title: Managing Partner


    9



    EXHIBIT NO.          DESCRIPTION

    Exhibit 1
    Joint Filing Agreement by and among the Reporting Persons, dated as of July 1, 2019 (incorporated herein by reference to Exhibit 1 to the Schedule 13G filed on July 2, 2019).
     

     
    10
    Get the next $NEOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NEOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NEOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience

      – The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at www.proxyvote.com, or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help stockholders vote their shares – DALLAS and FORT WORTH, Texas, March 12, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system

      3/12/21 9:04:16 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience

      – The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at www.proxyvote.com, or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help stockholders vote their shares – DALLAS and FORT WORTH, Texas, March 10, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system

      3/10/21 4:01:00 PM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • Hercules Capital Reports Fourth Quarter and Full-Year 2020 Financial Results

      PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the fourth quarter and full-year ended December 31, 2020. “Despite the unique challenges of 2020, Hercules was able to reach several new financial and operating milestones,” stated Scott Bluestein, chief executive officer and chief investment officer of Hercules. “Notably, we closed over $1.0 billion in new debt and equity commitments

      2/23/21 4:10:00 PM ET
      $ACEV
      $AYTU
      $ASPL
      $PACE
      Semiconductors
      Technology
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NEOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: M John Limongelli disposed to the issuer $0 worth of Common Stock (83,015 units at $0.00), decreasing direct ownership by 100% to 0 units

      4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

      3/19/21 6:26:34 PM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Jr. A. James Robinson disposed to the issuer $0 worth of Common Stock (23,453 units at $0.00), decreasing direct ownership by 100% to 0 units

      4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

      3/19/21 5:36:41 PM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: W. Gerald Mclaughlin disposed to the issuer $0 worth of Common Stock (270,171 units at $0.00), decreasing direct ownership by 100% to 0 units

      4 - Neos Therapeutics, Inc. (0001467652) (Issuer)

      3/19/21 5:35:56 PM ET
      $NEOS
      Major Pharmaceuticals
      Health Care

    $NEOS
    SEC Filings

    See more
    • SEC Form EFFECT filed by Neos Therapeutics, Inc.

      EFFECT - Neos Therapeutics, Inc. (0001467652) (Filer)

      3/26/21 12:15:43 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Neos Therapeutics, Inc.

      EFFECT - Neos Therapeutics, Inc. (0001467652) (Filer)

      3/26/21 12:15:26 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Neos Therapeutics, Inc.

      EFFECT - Neos Therapeutics, Inc. (0001467652) (Filer)

      3/26/21 12:15:21 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care

    $NEOS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for COTEMPLA XR-ODT issued to NEOS THERAPS INC

      Submission status for NEOS THERAPS INC's drug COTEMPLA XR-ODT (SUPPL-12) with active ingredient METHYLPHENIDATE has changed to 'Approval' on 10/13/2023. Application Category: NDA, Application Number: 205489, Application Classification: Labeling

      10/16/23 4:40:20 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • FDA Approval for COTEMPLA XR-ODT issued to NEOS THERAPS INC

      Submission status for NEOS THERAPS INC's drug COTEMPLA XR-ODT (SUPPL-7) with active ingredient METHYLPHENIDATE has changed to 'Approval' on 06/25/2021. Application Category: NDA, Application Number: 205489, Application Classification: Labeling

      6/28/21 5:08:40 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care

    $NEOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - Neos Therapeutics, Inc. (0001467652) (Subject)

      2/16/21 8:52:52 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Neos Therapeutics, Inc. (0001467652) (Subject)

      2/12/21 5:07:54 PM ET
      $NEOS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Neos Therapeutics, Inc. (0001467652) (Subject)

      2/12/21 6:47:18 AM ET
      $NEOS
      Major Pharmaceuticals
      Health Care